Different targets may help address treatment resistance and avoid re-exposure to previous targets3-5
What is currently known about GPRC5D expression?
- GPRC5D is expressed on the surface of multiple myeloma cells and non-malignant plasma cells1,4,6-9
Also expressed on healthy tissues, such as epithelial cells in keratinized tissues of the skin and tongue
- Expressed in a broad range of patients with multiple myeloma4
For example, GPRC5D expression has been detected in patients that varied according to disease staging, cytogenetic abnormalities, gender, and age
Expression is independent of other targets, including BCMA5
BCMA, B-cell maturation antigen; FDA, U.S. Food and Drug Administration; GPRC5D, G protein-coupled receptor class C group 5 member D; MOA, mechanism of action.
- TALVEY® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- U.S. FDA approves TALVEY® (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. News release. Janssen Biotech, Inc.; August 10, 2023. Accessed June 24, 2024. https://www.janssen.com/fda-approves-talveytm-talquetamab-tgvs-first-class-bispecific-therapy-treatment-patients-heavily
- Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371-1376.
- Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953-960.
- Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.
- Inoue S, Nambu T, Shimomura T. The RAIG family member, GPRC5D, is associated with hard-keratinized structures. J Invest Dermatol. 2004;122(3):565-573.
- Lancman G, Sastow DL, Cho HJ, et al. Bispecific antibodies in multiple myeloma: present and future. Blood Cancer Discov. 2021;2(5):423-433.
- Kodama T, Kochi Y, Nakai W, et al. Anti-GPRC5D/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther. 2019;18(9):1555-1564.
- Verkeij CPM, Broekmans MEC, van Duin M, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021;5(8):2196-2215.
- Bräuner-Osborne H, Jensen AA, Sheppard PO, et al. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. Biochim Biophys Acta. 2001;1518(3):237-248.
- TALVEY® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- U.S. FDA approves TALVEY® (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma. News release. Janssen Biotech, Inc.; August 10, 2023. Accessed June 24, 2024. https://www.janssen.com/fda-approves-talveytm-talquetamab-tgvs-first-class-bispecific-therapy-treatment-patients-heavily
- Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11(485):eaau7746.
- Pillarisetti K, Edavettal S, Mendonça M, et al. A T-cell- redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232-1243.